Risk of Dilution in Equity Value from Stock Options
First written in FY2016. 13 of 35 entries say "Worsened", first in FY2017-Q1. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026WorsenedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares from stock acquisition rights was 181,900, equivalent to 0.8% of the total 24,237,774 issued shares.」
The number of potential shares and the dilution ratio increased from 153,500 shares and 0.6% in the previous fiscal year to 181,900 shares and 0.8%, respectively. - FY2026-H1WorsenedAnnual report
「Series 17 Stock Acquisition Rights: Number of stock acquisition rights (units) 52,600; class, details and number of shares underlying the stock acquisition rights (shares): common shares, 52,600」
During the interim consolidated accounting period, the Company issued Series 17 Stock Acquisition Rights, adding potential dilution equivalent to 52,600 common shares. The exercise period runs from 20 June 2027 to 19 June 2035. - FY2025MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares from stock acquisition rights was 153,500, equivalent to 0.6% of the total 24,237,774 issued shares.」
The number of potential shares and the dilution ratio declined from 199,900 shares and 0.8% in the previous fiscal year to 153,500 shares and 0.6%, respectively. - FY2025-H1WorsenedAnnual report
「The stock acquisition rights issued during the interim consolidated accounting period were as follows. Series 16 Stock Acquisition Rights」
Series 16 Stock Acquisition Rights were granted to 8 Company employees and 10 subsidiary employees, adding potential dilution equivalent to 21,300 common shares. The exercise period runs from 21 June 2026 to 20 June 2034. - FY2024MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares from stock acquisition rights was 199,900, equivalent to 0.8% of the total 24,237,774 issued shares.」
The number of potential shares and the dilution ratio declined from 208,200 shares and 0.9% in the previous fiscal year to 199,900 shares and 0.8%, respectively. - FY2024-Q3RestatedAnnual report
「Series 14 Stock Acquisition Rights 34,800 units (34,800 common shares) Series 15 Stock Acquisition Rights 24,000 units (24,000 common shares)」
The Company disclosed details of the Series 14 and Series 15 Stock Acquisition Rights that were excluded from the calculation of diluted earnings per share. - FY2024-Q1WorsenedAnnual report
「15th Series Stock Acquisition Rights」
During the first quarter accounting period, the Company issued Series 15 Stock Acquisition Rights, adding potential dilution equivalent to 25,800 common shares. The exercise period runs from 17 June 2025 to 16 June 2033. - FY2023MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares from stock acquisition rights was 208,200, equivalent to 0.9% of the total 24,237,774 issued shares.」
The number of potential shares and the dilution ratio declined from 282,500 shares and 1.2% in the previous fiscal year to 208,200 shares and 0.9%, respectively. - FY2023-Q1WorsenedAnnual report
「Number of shares underlying the stock acquisition rights (shares) * 36,400 (Note 1)」
Series 14 Stock Acquisition Rights were issued, adding potential dilution equivalent to 36,400 common shares. - FY2022MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares from stock acquisition rights was 282,500, equivalent to 1.2% of the total 24,237,774 issued shares.」
The number of potential shares and the dilution ratio declined from 512,800 shares and 2.1% in the previous fiscal year to 282,500 shares and 1.2%, respectively. The issuance of Series 13 Stock Acquisition Rights covering 23,000 shares was also reported. - FY2022-Q2WorsenedAnnual report
「Series 12 Stock Acquisition Rights Number of shares underlying the stock acquisition rights (shares) * 17,000 (Note 1)」
During the second quarter accounting period, the Company issued Series 12 Stock Acquisition Rights to 3 employees, adding potential dilution equivalent to 17,000 shares. The exercise period runs from 16 September 2023 to 15 September 2031. - FY2022-Q1MaterialisedAnnual report
「1 June 2021–31 August 2021 (Note) 190,000 24,137,774 4 4,099 4 4,098 (Note) Increase resulting from the exercise of stock acquisition rights.」
190,000 shares were issued through the exercise of stock acquisition rights in the first quarter, bringing the total number of issued shares to 24,137,774. - FY2021MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by stock acquisition rights was 512,800, equivalent to 2.1% of the total 23,947,774 shares issued.」
Potential shares and the dilution ratio declined from 674,400 shares and 2.8% in the previous fiscal year to 512,800 shares and 2.1%, respectively. The issuance of stock acquisition rights underlying 148,800 shares as the Eleventh Series is also disclosed. - FY2021-Q2WorsenedAnnual report
「The stock acquisition rights issued during the second-quarter accounting period are as follows: Tenth Series of Stock Acquisition Rights. Number of shares underlying the stock acquisition rights (shares): 19,500」
The Tenth Series of Stock Acquisition Rights was issued for 15 employees, adding potential dilution exposure based on 19,500 shares. In addition, 25,000 shares were issued upon exercise during the same quarter. - FY2021-Q1MaterialisedAnnual report
「Between 1 June 2020 and 31 August 2020, the total number of shares issued increased by 45,000 and capital stock and capital reserves each increased by ¥10 million as a result of the exercise of stock acquisition rights.」
45,000 shares were issued as a result of the exercise of stock acquisition rights, and shares representing potential dilution were actually issued. - FY2020MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by stock acquisition rights was 674,400, equivalent to 2.8% of the total 23,877,774 shares issued.」
Potential shares stood at 674,400 and the dilution ratio was 2.8%, down from 742,300 shares and 3.1% in the previous fiscal year. - FY2020-Q3MaterialisedAnnual report
「Between 1 December 2019 and 29 February 2020, the total number of shares issued increased by 34,800 and capital stock and capital reserves each increased by ¥9 million as a result of the exercise of stock acquisition rights.」
34,800 shares were issued as a result of the exercise of stock acquisition rights, and shares representing potential dilution were actually issued. - FY2020-Q2MaterialisedAnnual report
「Between 1 September 2019 and 30 November 2019, the total number of shares issued increased by 16,000 and capital stock and capital reserves each increased by ¥3 million as a result of the exercise of stock acquisition rights.」
16,000 shares were actually issued as a result of the exercise of stock acquisition rights. - FY2020-Q1MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The total number of shares issued increased by 1,800 during the first quarter as a result of the exercise of stock acquisition rights, and shares representing potential dilution were actually issued. - FY2020-Q1WorsenedAnnual report
「The stock acquisition rights issued during the first quarter accounting period were as follows.」
Stock acquisition rights underlying 18,900 shares were issued for 14 employees as the Ninth Series of Stock Acquisition Rights, adding potential dilution exposure. - FY2019MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by stock acquisition rights was 742,300, equivalent to 3.1% of the total 23,799,774 shares issued.」
Potential shares stood at 742,300 and the dilution ratio was 3.1%, down from 2,007,300 shares and 8.9% in the previous fiscal year. - FY2019-Q3MaterialisedAnnual report
「1 December 2018–28 February 2019 162,574 23,799,774 35 4,046 35 4,046 (Note) Increase resulting from the exercise of stock acquisition rights.」
162,574 shares were issued during the third-quarter consolidated accounting period as a result of the exercise of stock acquisition rights, and shares representing potential dilution were actually issued. - FY2019-Q2MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The total number of shares issued increased by 28,200 between September and November 2018 as a result of the exercise of stock acquisition rights, and shares representing potential dilution were actually issued. - FY2019-Q1MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The total number of shares issued increased by 232,400 during the first quarter as a result of the exercise of stock acquisition rights, and shares representing potential dilution were actually issued. - FY2019-Q1WorsenedAnnual report
「The stock acquisition rights issued during the first quarter accounting period are as follows: Number of shares underlying the stock acquisition rights (shares): 85,000」
Stock acquisition rights underlying 85,000 common shares were issued as the Eighth Series of Stock Acquisition Rights, adding potential dilution exposure. - FY2018-Q3MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The total number of shares issued increased by 24,400 during the third-quarter accounting period as a result of the exercise of stock acquisition rights, and shares representing potential dilution were actually issued. - FY2018-Q2MaterialisedAnnual report
「582,000」
The total number of shares issued increased by 582,000 during the six-month period of the second quarter as a result of the exercise of stock acquisition rights, and the shares representing potential dilution were actually issued. - FY2018-Q1MaterialisedAnnual report
「402,400」
The total number of shares issued increased by 402,400 during the first quarter as a result of the exercise of stock acquisition rights, and the shares representing potential dilution were actually issued. - FY2017MitigatedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by stock acquisition rights was 2,007,300, equivalent to 8.9% of the total 22,490,200 shares issued.」
Although shares were issued upon the exercise of stock acquisition rights, potential shares at the end of the fiscal year stood at 2,007,300 and the dilution ratio was 8.9%, down from 2,418,000 shares and 11.0% in FY2016. - FY2017-Q3MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
The total number of shares issued increased by 38,700 during the third-quarter accounting period as shares were issued upon the exercise of stock acquisition rights. - FY2017-Q1WorsenedAnnual report
「The stock acquisition rights issued during the first quarter accounting period are as follows: Number of shares underlying the stock acquisition rights: 160,000 (Note) 1」
Stock acquisition rights underlying 160,000 shares were issued as the Seventh Series of Stock Acquisition Rights, adding potential dilution exposure. - FY2016First statedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by stock acquisition rights was 2,418,000, equivalent to 11.0% of the total 21,973,000 shares issued.」
The disclosure reports 2,418,000 potential shares, equivalent to 11.0% of total shares issued.